Learning to invest in doctors’ education
March 28, 2022 |
Pharmaceutical companies know doctors want high-value educational content. In a highly pressurised, cost-constrained healthcare environment with increasing demands for value and improved patient outcomes, time-poor doctors are calling out for more educational resources. However, the industry can find it hard to make a break from traditional methods of engaging with doctors, such as promotional communications and the traditional sales representative call to hospitals and GP surgeries.
This whitepaper explores exclusive new research highlighting the importance of educational and non-promotional clinical content to doctors, demonstrating why it should play an important part in any pharma engagement strategy.
By showing a commitment to doctors’ education, pharma companies make their interactions with these doctors more powerful, increasing the chances of long-term advocacy. This mutually beneficial approach meets the needs of both the company and the doctor.
There remains an important place for branded, promotional content and this whitepaper discusses how to balance the provision of promotional and nonpromotional content to create lasting, positive relationships with doctors. This not only helps fill gaps in their medical education but can build trust in the industry and ultimately improve patient care and outcomes.
The industry is well-used to taking a long-term approach to drug development cycles, therapy area endeavours and drug patent lifecycles. It’s time to be comfortable looking beyond the short-term for doctors’ education, too.
To read the full report please click here.
This content was provided by M3 (EU)
Company Details
Latest Content from M3 (EU)
The evolving world of pharma: trends challenges and opportunities
M3 EU recently surveyed 400 pharma marketers in the UK, Germany, France and Switzerland, and here’s what we heard: Budgets are shrinking, targets are climbing, and compliance requirements are getting…
Tailored and Targeted Pharmaceutical Marketing
Learn more about targeted personas for HCP marketing. If pharma companies want to differentiate themselves against their competition and produce impactful results they must be much bolder than the current state…
Learning to invest in doctors’ education
Pharmaceutical companies know doctors want high-value educational content. In a highly pressurised, cost-constrained healthcare environment with increasing demands for value and improved patient outcomes, time-poor doctors are calling out for…
Engaging doctors around the globe
Embedding a digital strategy as a prominent part of a pharmaceutical marketing campaign is becoming ever more important. Despite some perceived reluctance on the part of the industry, pharmaceutical companies…
How do doctors spend their time online?
In our recent research piece, Doctor networks: The rules of engagement for pharma, some overarching principles for online engagement between the pharmaceutical industry and doctors were defined.
How do doctors want to engage with pharma on new products?
More than 80% of European doctors agree they are interested in staying up-to-date with new developments about pharmaceutical products. But what influences their choice of treatment and how do they…
M3 Acquires MirVracha LCC in Russia Launching Full-Scale Development of Physician Platform Business in Russia
M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/; “M3” below) has announced the acquisition of MirVracha LCC (Headquarters: Moscow, Russia; CEO: Shotaro Yamamoto; “MirVracha” below), a website provider…
Revolutionising the Digital Content Delivery Model
Pharmaceutical industry processes don’t have to make the delivery of marketing campaigns slow and unmanageable, and thus ineffective. Changing working practices and really, truly thinking differently about how to deliver…
Healthcare in the Digital Age
Healthcare is changing. By understanding the needs of the physicians, and using innovative channels to make meaningful connections, pharma can ensure it continues to enjoy a mutually beneficial relationship.
M3 announces further expansion into Europe and Latin America with the acquisition of Vidal Group
M3 is strengthening and growing its global operations with the acquisition of Vidal Group, a trusted provider of prescribing information and clinical decision support services to doctors and other HCPs…
- 1
- 2